{"id":22699,"date":"2023-01-18T16:32:00","date_gmt":"2023-01-18T08:32:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22699"},"modified":"2025-01-23T16:37:25","modified_gmt":"2025-01-23T08:37:25","slug":"henlius-terminates-trop2-antibody-licensing-deal-with-chiome-bioscience","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22699","title":{"rendered":"Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience"},"content":{"rendered":"\n

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696<\/a>) has announced the termination of a licensing deal with Japan-based Chiome Bioscience Inc. effective January 17, 2023. The agreement, originally signed in January 2021, granted Henlius exclusive development, manufacturing, and commercialization rights to Chiome’s anti-trophoblast cell surface antigen 2 (TROP2) antibody. The decision to terminate the deal was influenced by the overly congested competitive landscape, which Henlius cited as impacting the commercial viability of the product.<\/p>\n\n\n\n

Original Agreement and Financial Terms<\/strong>
Under the 2021 agreement, Henlius paid Chiome USD 1 million upfront and committed to up to USD 23 million in milestone payments in exchange for the rights to Chiome’s TROP2 antibody product candidate in Greater China. The termination of the deal marks a strategic shift for Henlius, as the company navigates the competitive dynamics in the biopharmaceutical market.<\/p>\n\n\n\n

Future Outlook<\/strong>
With the termination of the TROP2 antibody licensing deal, Henlius is likely to reassess its pipeline and focus on other strategic opportunities. The move underscores the importance of market dynamics in shaping biopharmaceutical partnerships and highlights the need for companies to adapt to evolving competitive environments.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced the termination of a licensing deal…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3265,270,862],"class_list":["post-22699","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-chiome-bioscience","tag-henlius-biotech","tag-hkg-2696"],"yoast_head":"\nHenlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced the termination of a licensing deal with Japan-based Chiome Bioscience Inc. effective January 17, 2023. The agreement, originally signed in January 2021, granted Henlius exclusive development, manufacturing, and commercialization rights to Chiome's anti-trophoblast cell surface antigen 2 (TROP2) antibody. The decision to terminate the deal was influenced by the overly congested competitive landscape, which Henlius cited as impacting the commercial viability of the product.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22699\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22699\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-18T08:32:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-23T08:37:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22699#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22699\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience\",\"datePublished\":\"2023-01-18T08:32:00+00:00\",\"dateModified\":\"2025-01-23T08:37:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22699\"},\"wordCount\":191,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Chiome Bioscience\",\"Henlius Biotech\",\"HKG: 2696\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22699#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22699\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22699\",\"name\":\"Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-01-18T08:32:00+00:00\",\"dateModified\":\"2025-01-23T08:37:25+00:00\",\"description\":\"Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced the termination of a licensing deal with Japan-based Chiome Bioscience Inc. effective January 17, 2023. The agreement, originally signed in January 2021, granted Henlius exclusive development, manufacturing, and commercialization rights to Chiome's anti-trophoblast cell surface antigen 2 (TROP2) antibody. The decision to terminate the deal was influenced by the overly congested competitive landscape, which Henlius cited as impacting the commercial viability of the product.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22699#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22699\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22699#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience - Insight, China's Pharmaceutical Industry","description":"Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced the termination of a licensing deal with Japan-based Chiome Bioscience Inc. effective January 17, 2023. The agreement, originally signed in January 2021, granted Henlius exclusive development, manufacturing, and commercialization rights to Chiome's anti-trophoblast cell surface antigen 2 (TROP2) antibody. The decision to terminate the deal was influenced by the overly congested competitive landscape, which Henlius cited as impacting the commercial viability of the product.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22699","og_locale":"en_US","og_type":"article","og_title":"Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22699","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-01-18T08:32:00+00:00","article_modified_time":"2025-01-23T08:37:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22699#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22699"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience","datePublished":"2023-01-18T08:32:00+00:00","dateModified":"2025-01-23T08:37:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22699"},"wordCount":191,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Chiome Bioscience","Henlius Biotech","HKG: 2696"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22699#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22699","url":"https:\/\/flcube.com\/?p=22699","name":"Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-01-18T08:32:00+00:00","dateModified":"2025-01-23T08:37:25+00:00","description":"Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced the termination of a licensing deal with Japan-based Chiome Bioscience Inc. effective January 17, 2023. The agreement, originally signed in January 2021, granted Henlius exclusive development, manufacturing, and commercialization rights to Chiome's anti-trophoblast cell surface antigen 2 (TROP2) antibody. The decision to terminate the deal was influenced by the overly congested competitive landscape, which Henlius cited as impacting the commercial viability of the product.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22699#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22699"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22699#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22699"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22699\/revisions"}],"predecessor-version":[{"id":22701,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22699\/revisions\/22701"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}